Precision biosciences stock.
Stock Quote. Change. Volume. Today's Open. Previous Close. Today's High. Today's Low. 52 Week High. 52 Week Low.
Precision BioSciences, Inc. : Forcasts, revenue, earnings, analysts expectations, ratios for Precision BioSciences, Inc. Stock | DTIL | US74019P1084precisionbiosciences .com. Precision BioSciences, Inc. is a publicly traded American clinical stage gene editing company headquartered in Durham, North Carolina. [3] Founded in 2006, Precision is focused on developing both in vivo and ex vivo gene editing therapies using its proprietary "ARCUS" genome editing platform. [4] Nov 29, 2023 · The Precision BioSciences stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention. A Different Perspective. Precision BioSciences shareholders are down 73% for the year, falling short of the market return. The market shed around 12%, no doubt weighing on the stock price.Precision BioSciences Reports Fourth Quarter and Fiscal Year 2021 Financial Results and Provides Business Update. March 15, 2022 at 7:00 AM EDT. ... Weighted average shares of common stock outstanding - basic and diluted 58,688,102 52,031,740 Precision Biosciences, Inc. Consolidated Balance Sheets Data ...
Source Headline; Precision BioSciences, Inc. (DTIL) finance.yahoo.com - November 30 at 1:02 PM Precision BioSciences to Present at Hep-DART 2023 finance.yahoo.com - November 30 at 8:02 AM: Precision BioSciences Announces Grant of Inducement Award Under Nasdaq Listing Rule 5635(c)(4) finance.yahoo.com - …The latest price target for Precision BioSciences ( NASDAQ: DTIL) was reported by HC Wainwright & Co. on Tuesday, September 19, 2023. The analyst firm set a price target for 3.00 expecting DTIL to ...The general public, who are usually individual investors, hold a 29% stake in Precision BioSciences. While this size of ownership may not be enough to sway a policy decision in their favour, they can still make a collective impact on company policies. Public Company Ownership. Public companies currently own 15% of Precision BioSciences …
Precision BioSciences Receives Approval from The Nasdaq Stock Market LLC to Transfer the Listing of its Common Stock from the Nasdaq Global Select Market to the Nasdaq Capital Market Oct 26 Price target decreased by 15% to US$2.603 equities research analysts have issued 1 year price targets for Precision BioSciences' stock. Their DTIL share price targets range from $2.00 to $4.00. On average, they expect the company's stock price to reach $3.00 in the next twelve months. This suggests a possible upside of 624.6% from the stock's current price.
7 ngày trước ... ... Precision BioSciences' common stock at $0.42 each. The stock option comes with a vesting schedule spread over four years, with one-quarter ...Patrick Trucchio, an analyst from H.C. Wainwright, reiterated the Buy rating on Precision BioSciences (DTIL – Research Report). The associated price target is $3.00. Patrick Trucchio has given ...HC Wainwright Adjusts Price Target on Precision BioSciences to $3 From $5, Keeps Buy Rating. Aug. 17. MT. BMO Capital Downgrades Precision BioSciences to Market Perform From Outperform, Adjusts Price Target to $4 From $7. Mar. 14. MT. Goldman Sachs Adjusts Price Target on Precision BioSciences to $1 From $2, Maintains Neutral Rating. Nov. 10. MT.Precision Biosciences has been on a roll with positive updates in both their CAR T-Cell and gene editing pipelines. Find out why I rate DTIL stock a Buy.13 thg 4, 2021 ... Do you want to earn up to a 4888583% annual return on your money by two trades per day on Precision Biosciences Inc DTIL Stock? Reading this ...
About Precision BioSciences, Inc. Precision BioSciences, Inc. is a clinical stage biotechnology company dedicated to improving life (DTIL) with its novel and proprietary ARCUS® genome editing platform. ARCUS is a highly specific and versatile genome editing platform that was designed with therapeutic safety, delivery, and control …
Precision BioSciences (DTIL) Company Description: Precision BioSciences, Inc. is a biotechnology company, which engages in the development of genome editing technologies. It operates through the ...
Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion, excision, and elimination, today announced publication in the journal Nature Metabolism of a peer reviewed manuscript titled “ Efficient elimination of MELAS-associated m ...Nov 9, 2023 · On November 7, 2023, Precision BioSciences Inc (DYAI) stock showed promising performances based on the information provided. According to data from CNN Money, the four analysts offering 12-month price forecasts for DYAI had a median target of $3.00, with a high estimate of $4.00 and a low estimate of $2.00. Precision BioSciences, Inc. Common Stock (DTIL) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets.The stock currently has a share float of 51.43%. Precision Biosciences Inc stock is held by 114 institutions, with Great Point Partners LLC being the largest institutional investor. By Jun 29, 2023, it held 6.49% of the shares, which is about 7.47 million shares worth $3.93 million.About Precision BioSciences, Inc. ... risks related to ownership of our common stock and other important factors discussed under the caption “Risk Factors” in our Quarterly Report on Form 10 ...Additionally, Precision announced a common stock offering yesterday. The company will “sell 35,971,224 shares of its common stock at a price of $1.39 per share.”
Precision BioSciences (DTIL) JonesTrading analyst Soumit Roy reiterated a Buy rating on Precision BioSciences today and set a price target of $4.00. The company’s shares closed last Wednesday at ...Precision BioSciences, Inc. (DTIL) announced the approval of an inducement award for a new employee under the 2021 Employment Inducement Incentive Award Plan. The award consists of a stock option to purchase 160,000 shares of Precision's common stock at an exercise price of $0.42 per share, with a 10-year term …About Precision BioSciences, Inc. Precision BioSciences, Inc. is a clinical stage biotechnology company dedicated to improving life (DTIL) with its novel and proprietary ARCUS® genome editing platform. ARCUS is a highly specific and versatile genome editing platform that was designed with therapeutic safety, delivery, and control …20 thg 11, 2020 ... Precision BioSciences, Inc. is a clinical stage biotechnology company dedicated to improving life (DTIL) with its novel and proprietary ARCUS® ...Precision BioSciences, Inc. (Nasdaq: DTIL) will present at Hep-DART 2023 in Los Cabos, Mexico, showcasing their PBGENE-HBV Program for gene editing ...Precision Biosciences Inc. Watch list NEW Set a price target alert Open Last Updated: Dec 1, 2023 9:53 a.m. EST Real time quote $ 0.3645 0.0094 2.65% Previous Close $0.3551 Advanced Charting...
Valuation metrics show that Precision BioSciences, Inc. may be undervalued. Its Value Score of B indicates it would be a good pick for value investors. The financial health and growth prospects of ...7 ngày trước ... DURHAM, N.C.–(BUSINESS WIRE)–Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ...
Nov 29, 2023 · The Precision BioSciences stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention. When it comes to precision cutting, having the right tool can make all the difference. That’s where the Super Cutter comes in. This innovative tool is designed to provide unparalleled accuracy and precision, making it a must-have for any DI...Precision BioSciences shares are trading lower after HC Wainwright maintained a Buy rating on the stock but lowered its price target from $5 to $3. Benzinga Newsdesk - Aug 17, 2023, 11:06AMDURHAM, N.C.--(BUSINESS WIRE)--Jun. 8, 2022-- Precision BioSciences, Inc. (Nasdaq: DTIL) a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced its latest program updates across its allogeneic CAR T pipeline. The Company provided new …Jun 22, 2023 · Stifel Nicolaus Adjusts Precision BioSciences Price Target to $9 From $11, Maintains Buy Rating. Goldman Sachs Adjusts Precision BioSciences' Price Target to $2 From $3, Keeps Neutral Rating. More news. Press releases Precision BioSciences, Inc. Precision BioSciences Reports Second Quarter 2023 Financial Results and Provides Business Update. Track Precision Biosciences Inc (DTIL) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investors28 thg 3, 2019 ... Precision Biosciences, the gene-editing startup, started trading on the Nasdaq stock exchange today after raising a $126.4 million IPO ...Precision BioSciences Reports Third Quarter 2023 Financial Results and Provides Business Update. November 7, 2023 at 7:00 AM EST. PDF Version ... Weighted average shares of common stock outstanding-basic and diluted 115,174,752 110,849,196 Precision Biosciences, Inc. Condensed Balance Sheets Data ...
Find the latest Precision BioSciences, Inc. (DTIL) stock discussion in Yahoo Finance's forum. Share your opinion and gain insight from other stock traders and investors.
Precision BioSciences (DTIL) Company Description: Precision BioSciences, Inc. is a biotechnology company, which engages in the development of genome editing technologies. It operates through the ...Precision BioSciences Inc is a genome editing company dedicated to improving life through its genome editing platform, ARCUS. It leverages ARCUS in the development of its product candidates, which are designed to treat human diseases and provide food and agricultural solutions. ARCUS is also unique in its relatively small size which potentially ...View the latest Precision Biosciences Inc. (DTIL) stock price, news, historical charts, analyst ratings and financial information from WSJ.28 thg 3, 2019 ... Precision Biosciences, the gene-editing startup, started trading on the Nasdaq stock exchange today after raising a $126.4 million IPO ...Apple Inc. Common Stock. $191.45 +1.76 +0.93%. Precision BioSciences, Inc. Common Stock (DTIL) Real-time Stock Quotes - Nasdaq offers real-time quotes & market activity …These 4 analysts have an average price target of $6.75 versus the current price of Precision BioSciences at $0.525, implying upside. Below is a summary of how these 4 analysts rated Precision ...Jan 24, 2022 · This free interactive report on Precision BioSciences' balance sheet strength is a great place to start, if you want to investigate the stock further. A Different Perspective. Given that the market gained 5.6% in the last year, Precision BioSciences shareholders might be miffed that they lost 65%. Precision BioSciences (NASDAQ: DTIL), a biotechnology firm focusing on gene editing, announced that on November 21, the company's Compensation Committee authorized an inducement stock option for a new hire under the Nasdaq Listing Rule 5635(c)(4). The inducement, part of their Inducement Award Plan, allows the employee …Which Precision BioSciences insiders have been selling company stock? The following insiders have sold DTIL shares in the last 24 months: Alan List ($32,602.70), Dario Scimeca ($39,689.22), Derek Jantz ($38,828.94), …
Precision BioSciences market cap as of November 07, 2023 is $0.05B . Precision BioSciences market cap history and chart from 2018 to 2023. Market capitalization (or market value) is the most commonly used method of measuring the size of a publicly traded company and is calculated by multiplying the current stock price by the number of shares ...Precision Biosciences Stock Earnings. The value each DTIL share was expected to gain vs. the value that each DTIL share actually gained. Precision Biosciences ( DTIL) reported Q3 2023 earnings per share (EPS) of -$0.14, beating estimates of -$0.18 by 21.37%. In the same quarter last year, Precision Biosciences 's earnings per share (EPS) was ...Overview Stock Screener Earnings Calendar Sectors Nasdaq | DTIL U.S.: Nasdaq Precision Biosciences Inc. Watch list NEW Set a price target alert Open Last Updated: …Precision BioSciences, Inc is a clinical-stage gene editing company. It is developing ex vivo allogeneic chimeric antigen receptor (CAR) T immunotherapies and in vivo therapies for genetic and infectious diseases with the application of its owned ARCUS genome editing platform.Instagram:https://instagram. stock charts appspy stock after hoursplaystation stockscsg field service management Stifel Nicolaus Adjusts Precision BioSciences Price Target to $9 From $11, Maintains Buy Rating. Goldman Sachs Adjusts Precision BioSciences' Price Target to $2 From $3, Keeps Neutral Rating. More news. Press releases Precision BioSciences, Inc. Precision BioSciences Reports Second Quarter 2023 Financial Results and Provides Business Update. ceo of chevronoxlc stock dividend Dec 1, 2023 · A high-level overview of Precision BioSciences, Inc. (DTIL) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. 16 thg 8, 2023 ... Precision BioSciences hands global rights to CAR-T candidate; Sagimet closes underwriter's option to buy stock ... Precision BioSciences said ... will spy go up tomorrow Precision BioSciences, Inc. Common Stock (DTIL) Pre-Market Stock Quotes - Nasdaq offers pre-market quotes and pre-market activity data for US and global markets. Nov 24, 2023 · Checkpoint Therapeutics (NASDAQ:CKPT) and Precision BioSciences (NASDAQ:DTIL) are both small-cap medical companies, but which is the better investment?We will compare the two businesses based on the strength of their community ranking, risk, dividends, profitability, earnings, analyst recommendations, institutional ownership, valuation and media sentiment.